|
Hello Immunization Partners,
Please share the following information with providers in your jurisdiction.
On December 19, 2024, the Michigan Department of Health and Human Services (MDHHS) Division of Immunization sent an email message titled: MMWR Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine. As an addendum to that email, providers need to be aware that the Michigan Care Improvement Registry (MCIR) is not currently reflecting this updated vaccine recommendation. An additional email will be sent when MCIR programming reflects this updated recommendation.
Providers should follow the Advisory Committee on Immunization Practices (ACIP) recommendation noted in the December 19, 2024, email message and MMWR entitled New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, October 2024.
It is also important to note that there is no recommendation to administer additional doses to persons vaccinated with MenB-4C before October 24, 2024, using a 0- and 1- month dosing schedule. Persons who have completed a MenB vaccine primary series and who remain or become at increased risk for invasive meningococcal disease are recommended to receive booster vaccination. Booster doses need to be from the same manufacturer used for doses in the primary series.
Thank you for all you do to protect Michiganders from vaccine preventable diseases.
Your Immunization Outreach and Education Team,
Alyssa, Andrea, Dianne, Heidi, and Sarah
|
